Hyderabad-based Suven Life Sciences Limited (Suven) said that its clinical drug candidate SUVN-502, being developed for central nervous system (CNS) disorders, had completed all the long-term chronic studies.
“We are very pleased with the excellent outcome of all chronic and developmental tox studies for our clinical candidate SUVN-502, which is being developed for CNS disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia and the potential market opportunity is more than $20 billion globally,” Suven’s chief executive officer, Venkat Jasti, stated in a press release.
Jasti said various pharmaceutical companies had evinced interest in the drug and Suven was considering about possible partnerships in the near future. Simultaneously, the company was engaged in filing an investigational new drug application (IND) with the US FDA to support initiation of Phase II, a proof of concept (PoC), clinical trials in CNS patients during this year.
Phase I trials of the drug on humans were conducted in Switzerland, the release added.